{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:51:13Z","timestamp":1787698273380,"version":"build-2784847793"},"reference-count":181,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T00:00:00Z","timestamp":1702857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Human body cells are stem cell (SC) derivatives originating from bone marrow. Their special characteristics include their capacity to support the formation and self-repair of the cells. Cancer cells multiply uncontrollably and invade healthy tissues, making stem cell transplants a viable option for cancer patients undergoing high-dose chemotherapy (HDC). When chemotherapy is used at very high doses to eradicate all cancer cells from aggressive tumors, blood-forming cells and leukocytes are either completely or partially destroyed. Autologous stem cell transplantation (ASCT) is necessary for patients in those circumstances. The patients who undergo autologous transplants receive their own stem cells (SCs). The transplanted stem cells first come into contact with the bone marrow and then undergo engraftment, before differentiating into blood cells. ASCT is one of the most significant and innovative strategies for treating diseases. Here we focus on the treatment of Hodgkin\u2019s lymphoma, non-Hodgkin\u2019s lymphoma, multiple myeloma, and AL amyloidosis, using ASCT. This review provides a comprehensive picture of the effectiveness and the safety of ASCT as a therapeutic approach for these diseases, based on the currently available evidence.<\/jats:p>","DOI":"10.3390\/cells12242855","type":"journal-article","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T05:41:35Z","timestamp":1702878095000},"page":"2855","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Autologous Stem Cell Transplant in Hodgkin\u2019s and Non-Hodgkin\u2019s Lymphoma, Multiple Myeloma, and AL Amyloidosis"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8678-5029","authenticated-orcid":false,"given":"Sulaiman Mohammed","family":"Alnasser","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Toxicology, Unaizah College of Pharmacy, Qassim University, Buraydah 51452, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid Saad","family":"Alharbi","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Unaizah College of Pharmacy, Qassim University, Buraydah 51452, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali F.","family":"Almutairy","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Unaizah College of Pharmacy, Qassim University, Buraydah 51452, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sulaiman Mohammed","family":"Almutairi","sequence":"additional","affiliation":[{"name":"Unaizah College of Pharmacy, Qassim University, Buraydah 52571, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulmalik Mohammed","family":"Alolayan","sequence":"additional","affiliation":[{"name":"Unaizah College of Pharmacy, Qassim University, Buraydah 52571, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,18]]},"reference":[{"key":"ref_1","unstructured":"Sapkota, A. (2022, April 12). Stem Cells-Definition, Properties, Types, Uses, Challenges. Available online: https:\/\/microbenotes.com\/stem-cells\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.21037\/sci.2019.06.04","article-title":"Stem cell-based regenerative medicine","volume":"6","author":"Rajabzadeh","year":"2019","journal-title":"Stem Cell Investig."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"753","DOI":"10.25259\/IJDVL_19_20","article-title":"Stem cell therapy in dermatology","volume":"87","author":"Khandpur","year":"2021","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.biotechadv.2018.03.011","article-title":"Stem cells: Their source, potency and use in regenerative therapies with focus on adipose-derived stem cells\u2014A review","volume":"36","author":"Bacakova","year":"2018","journal-title":"Biotechnol. Adv."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Casado-D\u00edaz, A. (2022). Stem Cells in Regenerative Medicine. J. Clin. Med., 11.","DOI":"10.3390\/jcm11185460"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"92","DOI":"10.22270\/ajprd.v7i5.558","article-title":"Stem Cell Therapy-An Overview","volume":"7","author":"Jagiri","year":"2019","journal-title":"Asian J. Pharm. Res. Dev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12015-019-09935-x","article-title":"Advances in pluripotent stem cells: History, mechanisms, technologies, and applications","volume":"16","author":"Liu","year":"2020","journal-title":"Stem Cell Rev. Rep."},{"key":"ref_8","first-page":"6","article-title":"Multipotent stem cell and current application","volume":"55","author":"Sobhani","year":"2017","journal-title":"Acta Medica Iran."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13287-019-1165-5","article-title":"Stem cells: Past, present, and future","volume":"10","author":"Zakrzewski","year":"2019","journal-title":"Stem Cell Res. Ther."},{"key":"ref_10","first-page":"1275","article-title":"Stem cells and its multimodality\u2014A review","volume":"13","author":"Sutharshan","year":"2022","journal-title":"J. Pharm. Negat. Results"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"21","DOI":"10.15283\/ijsc.2016.9.1.21","article-title":"Recent stem cell advances: Cord blood and induced pluripotent stem cell for cardiac regeneration-a review","volume":"9","author":"Medhekar","year":"2016","journal-title":"Int. J. Stem Cells"},{"key":"ref_12","first-page":"919","article-title":"Stem cell: Basics, classification and applications","volume":"2","author":"Kalra","year":"2014","journal-title":"Am. J. Phytomed. Clin. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Singh, V.K., Saini, A., Kalsan, M., Kumar, N., and Chandra, R. (2016). Describing the stem cell potency: The various methods of functional assessment and in silico diagnostics. Front. Cell Dev. Biol., 4.","DOI":"10.3389\/fcell.2016.00134"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3389\/fonc.2019.00068","article-title":"Quantitative evaluation of intraventricular delivery of therapeutic neural stem cells to orthotopic glioma","volume":"9","author":"Gutova","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"615508","DOI":"10.3389\/fped.2021.615508","article-title":"A review of placenta and umbilical cord-derived stem cells and the immunomodulatory basis of their therapeutic potential in bronchopulmonary dysplasia","volume":"9","author":"Chia","year":"2021","journal-title":"Front. Pediatr."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.pmbts.2018.07.009","article-title":"Adult stem cells for regenerative therapy","volume":"160","author":"Gurusamy","year":"2018","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Chu, D.T., Nguyen, T.T., Tien, N.L.B., Tran, D.K., Jeong, J.H., Anh, P.G., Thanh, V.V., Truong, D.T., and Dinh, T.C. (2020). Recent Progress of Stem Cell Therapy in Cancer Treatment: Molecular Mechanisms and Potential Applications. Cells, 9.","DOI":"10.3390\/cells9030563"},{"key":"ref_18","first-page":"63","article-title":"Induced pluripotent stem cells and their potential for basic and clinical sciences","volume":"9","author":"Ye","year":"2013","journal-title":"Curr. Cardiol. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2217\/rme-2022-0045","article-title":"Clinical applications of pluripotent stem cells and their derivatives: Current status and future perspectives","volume":"17","author":"Pendse","year":"2022","journal-title":"Regen. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"146748","DOI":"10.1016\/j.gene.2022.146748","article-title":"Stem Cell Challenge in Cancer Progression, Oncology and Therapy","volume":"840","author":"Alnasser","year":"2022","journal-title":"Gene"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1590\/S0100-879X2006005000166","article-title":"The use of stem cells for the treatment of autoimmune diseases","volume":"40","author":"Rosa","year":"2007","journal-title":"Braz. J. Med. Biol. Res."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Adami, R., Scesa, G., and Bottai, D. (2014). Stem cell transplantation in neurological diseases: Improving effectiveness in animal models. Front. Cell Dev. Biol., 2.","DOI":"10.3389\/fcell.2014.00017"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1365-2184.2008.00487.x","article-title":"Stem cells and genetic disease","volume":"41","author":"Silburn","year":"2008","journal-title":"Cell Prolif."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"hoy024","DOI":"10.1093\/hropen\/hoy024","article-title":"Two decades of embryonic stem cells: A historical overview","volume":"2019","author":"Eguizabal","year":"2019","journal-title":"Hum. Reprod. Open"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1093\/neuonc\/now096","article-title":"Stem cell-based therapies for tumors in the brain: Are we there yet?","volume":"18","author":"Shah","year":"2016","journal-title":"Neuro-oncology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.3389\/fimmu.2018.01412","article-title":"Immune curbing of cancer stem cells by CTLs directed to NANOG","volume":"9","author":"Wefers","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_27","first-page":"1","article-title":"Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3747\/co.26.5033","article-title":"A general practitioner\u2019s guide to hematopoietic stem-cell transplantation","volume":"26","author":"Bazinet","year":"2019","journal-title":"Curr. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2174\/157339406777934717","article-title":"Cancer therapy-induced residual bone marrow injury: Mechanisms of induction and implication for therapy","volume":"2","author":"Wang","year":"2006","journal-title":"Curr. Cancer Ther. Rev."},{"key":"ref_30","unstructured":"Champlin, Q.B.A.R. (2014). Abeloff\u2019s Clinical Oncology, Elsevier Inc.. [5th ed.]."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Carreras, E., Dufour, C., Mohty, M., and Kr\u00f6ger, N. (2019). The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies, Springer International Publishing.","DOI":"10.1007\/978-3-030-02278-5"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.4103\/jfmpc.jfmpc_1037_19","article-title":"Non-Hodgkin\u2019s lymphoma: A review","volume":"9","author":"Singh","year":"2020","journal-title":"J. Fam. Med. Prim. Care"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Momotow, J., Borchmann, S., Eichenauer, D.A., Engert, A., and Sasse, S. (2021). Hodgkin lymphoma\u2014Review on pathogenesis, diagnosis, current and future treatment approaches for adult patients. J. Clin. Med., 10.","DOI":"10.3390\/jcm10051125"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J. Clin."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.semradonc.2009.09.006","article-title":"Hodgkin lymphoma across the age spectrum: Epidemiology, therapy, and late effects","volume":"20","author":"Punnett","year":"2010","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_36","unstructured":"Ansell, S.M. (2015). Mayo Clinic Proceedings, Elsevier."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"iv19","DOI":"10.1093\/annonc\/mdy080","article-title":"Clinical practice guidelines: Hodgkin lymphoma","volume":"29","author":"Eichenauer","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/ajh.26717","article-title":"Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management","volume":"97","author":"Ansell","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: A randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1200\/JCO.2003.11.103","article-title":"High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin\u2019s lymphoma responding to front-line therapy","volume":"21","author":"Federico","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3324\/haematol.13484","article-title":"High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin\u2019s lymphoma responding to front-line therapy: Long-term results","volume":"94","author":"Carella","year":"2009","journal-title":"Haematologica"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11899-017-0382-1","article-title":"A review of autologous stem cell transplantation in lymphoma","volume":"12","author":"Zahid","year":"2017","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"10","DOI":"10.5581\/1516-8484.20110007","article-title":"Autologous hematopoietic stem cell transplantation in classical Hodgkin\u2019s lymphoma","volume":"33","author":"Cortez","year":"2011","journal-title":"Rev. Bras. Hematol. E Hemoter."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: Results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1200\/JCO.2010.30.5771","article-title":"Dose intensity of chemotherapy in patients with relapsed Hodgkin\u2019s lymphoma","volume":"28","author":"Josting","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Castagna, L., Carlo-Stella, C., Mazza, R., and Santoro, A. (2015). Current role of autologous and allogeneic stem cell transplantation for relapsed and refractory hodgkin lymphoma. Mediterr. J. Hematol. Infect. Dis.","DOI":"10.4084\/mjhid.2015.015"},{"key":"ref_47","unstructured":"von Tresckow, B., and Moskowitz, C.H. (2016). Seminars in Hematology, Elsevier."},{"key":"ref_48","unstructured":"Sureda, A., and Mart\u00ednez, C. (2019). The EBMT Handbook."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.bbmt.2017.12.798","article-title":"Tandem autologous hematopoietic cell transplantation for patients with primary progressive or recurrent Hodgkin lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410\/BMT CTN 0703)","volume":"24","author":"Smith","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"key":"ref_52","first-page":"k3204","article-title":"Non-Hodgkin lymphoma","volume":"362","author":"Ajithkumar","year":"2018","journal-title":"BMJ"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Thandra, K.C., Barsouk, A., Saginala, K., Padala, S.A., Barsouk, A., and Rawla, P. (2021). Epidemiology of Non-Hodgkin\u2019s Lymphoma. Med. Sci., 9.","DOI":"10.3390\/medsci9010005"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e461","DOI":"10.1097\/HS9.0000000000000461","article-title":"Controversies in the Treatment of Peripheral T-cell Lymphoma","volume":"4","author":"Bachy","year":"2020","journal-title":"HemaSphere"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01","volume":"30","author":"Relander","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.bbmt.2015.01.013","article-title":"Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease","volume":"21","author":"Beitinjaneh","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous Stem-Cell Transplantation As First-Line Therapy in Peripheral T-Cell Lymphomas: Results of a Prospective Multicenter Study","volume":"27","author":"Reimer","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/leu.2014.79","article-title":"Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma","volume":"28","author":"Corradini","year":"2014","journal-title":"Leukemia"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/bmt.2010.92","article-title":"Long-term outcomes after hematopoietic SCT for adult T-cell leukemia\/lymphoma: Results of prospective trials","volume":"46","author":"Choi","year":"2011","journal-title":"Bone Marrow Transplant."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"15","DOI":"10.17116\/terarkh201587715-25","article-title":"Autologous hematopoietic stem cell transplantation as late high-dose consolidation in adult patients with T-cell lymphoblastic leukemias: Results of a Russian multicenter study","volume":"87","author":"Parovichnikova","year":"2015","journal-title":"Ter. Arkhiv"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA A Cancer J. Clin."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa1301077","article-title":"Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin\u2019s Lymphoma","volume":"369","author":"Stiff","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1038\/sj.leu.2404781","article-title":"Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: A multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi)","volume":"21","author":"Tarella","year":"2007","journal-title":"Leukemia"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.3324\/haematol.2009.007005","article-title":"Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: A phase II multicenter study","volume":"94","author":"Vitolo","year":"2009","journal-title":"Haematologica"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s00277-016-2729-4","article-title":"The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase","volume":"95","author":"Kim","year":"2016","journal-title":"Ann. Hematol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"5812","DOI":"10.4081\/hr.2015.5812","article-title":"Favorable Event Free-Survival of High-Dose Chemotherapy followed by Autologous Hematopoietic Stem Cell Transplantation for Higher Risk Diffuse Large B-Cell Lymphoma in First Complete Remission","volume":"7","author":"Kaneko","year":"2015","journal-title":"Hematol. Rep."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1007\/s00277-021-04650-5","article-title":"The role of autologous stem cell transplantation (ASCT) in aggressive B-cell lymphomas: Real-world data from a retrospective single-center analysis","volume":"100","author":"Wullenkord","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","article-title":"Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12","volume":"32","author":"Crump","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_69","first-page":"1800","article-title":"Outcomes in refractory aggressive diffuse large b-cell lymphoma (DLBCL): Results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Carreras, E., Dufour, C., Mohty, M., and Kr\u00f6ger, N. (2018). The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies, Springer International Publishing.","DOI":"10.1007\/978-3-030-02278-5"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/bmt.2015.6","article-title":"Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: Current practice in Europe 2015","volume":"50","author":"Sureda","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1182\/blood-2017-02-766691","article-title":"FDG-PET\u2013driven consolidation strategy in diffuse large B-cell lymphoma: Final results of a randomized phase 2 study","volume":"130","author":"Casasnovas","year":"2017","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Carreras, E., Dufour, C., Mohty, M., and Kr\u00f6ger, N. (2019). The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies, Springer International Publishing.","DOI":"10.1007\/978-3-030-02278-5"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2004-03-0982","article-title":"Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: Results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group","volume":"104","author":"Lenz","year":"2004","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1182\/blood-2007-10-116749","article-title":"Prospective, multicenter randomized GITMO\/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: The superior disease control of R-HDS does not translate into an overall survival advantage","volume":"111","author":"Ladetto","year":"2008","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","article-title":"High-Dose Therapy Improves Progression-Free Survival and Survival in Relapsed Follicular Non-Hodgkin\u2019s Lymphoma: Results From the Randomized European CUP Trial","volume":"21","author":"Schouten","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and Management of Multiple Myeloma: A Review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1200\/JOP.19.00335","article-title":"Autologous Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Therapies","volume":"16","author":"Parrondo","year":"2020","journal-title":"JCO Oncol. Pract."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Carreras, E., Dufour, C., Mohty, M., and Kr\u00f6ger, N. (2019). The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies, Springer International Publishing.","DOI":"10.1007\/978-3-030-02278-5"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"204062071988811","DOI":"10.1177\/2040620719888111","article-title":"Stem-cell transplantation in multiple myeloma: How far have we come?","volume":"10","author":"Soekojo","year":"2019","journal-title":"Ther. Adv. Hematol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/2040620718761776","article-title":"The evolution of stem-cell transplantation in multiple myeloma","volume":"9","author":"Mahajan","year":"2018","journal-title":"Ther. Adv. Hematol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1038\/bmt.2017.198","article-title":"Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: A center for international blood and marrow transplant research analysis","volume":"52","author":"Mahindra","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1056\/NEJMct0805626","article-title":"Autologous hematopoietic stem-cell transplantation for multiple myeloma","volume":"360","author":"Harousseau","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood-2009-05-222539","article-title":"A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma","volume":"115","author":"Lokhorst","year":"2010","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","article-title":"Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: Results of the IFM 2005-01 phase III trial","volume":"28","author":"Harousseau","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3324\/haematol.2011.043372","article-title":"Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results","volume":"97","author":"Morgan","year":"2012","journal-title":"Haematologica"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: Results of the randomized phase III HOVON-65\/GMMG-HD4 trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","article-title":"Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: A randomised phase 3 study","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2016-01-693580","article-title":"VTD is superior to VCD prior to intensive therapy in multiple myeloma: Results of the prospective IFM2013-04 trial","volume":"127","author":"Moreau","year":"2016","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1200\/JCO.2011.39.5137","article-title":"Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma","volume":"31","author":"Ludwig","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1200\/JCO.2010.28.3945","article-title":"Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p)","volume":"28","author":"Leleu","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2012.48.4626","article-title":"Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: A meta-analysis of phase III randomized, controlled trials","volume":"31","author":"Sonneveld","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1182\/blood-2012-02-408922","article-title":"Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: A randomized phase 3 PETHEMA\/GEM study","volume":"120","author":"Oriol","year":"2012","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): A randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1200\/JCO.2013.54.8164","article-title":"Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: A phase II study by the Intergroupe Francophone du My\u00e9lome","volume":"32","author":"Roussel","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","article-title":"Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Moreau","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-020-0311-8","article-title":"Longer term follow-up of the randomized phase III trial SWOG S0777: Bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)","volume":"10","author":"Durie","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1182\/blood.2019000241","article-title":"Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma","volume":"134","author":"Oriol","year":"2019","journal-title":"Blood"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1200\/JCO.19.02515","article-title":"Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma","volume":"38","author":"Joseph","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1080\/10428194.2021.1992763","article-title":"Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance","volume":"63","author":"Gaballa","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1182\/blood-2018-99-112659","article-title":"Integrated Analysis of Randomized Controlled Trials Evaluating Bortezomib + Lenalidomide + Dexamethasone or Bortezomib + Thalidomide + Dexamethasone Induction in Transplant-Eligible Newly Diagnosed Multiple Myeloma","volume":"132","author":"Hebraud","year":"2018","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(20)30452-6","article-title":"Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): A multicentre, open-label, phase 3, randomised, controlled trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","article-title":"Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): A randomised, open-label, phase 2 trial","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): A randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: The GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone with Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1001\/jamaoncol.2021.0611","article-title":"Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial","volume":"7","author":"Landgren","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1182\/blood-2021-146040","article-title":"Daratumumab Plus Ixazomib, Lenalidomide, and Dexamethasone as Extended Induction and Consolidation Followed By Lenalidomide Maintenance in Standard-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (IFM 2018-01): A Phase II Study of the Intergroupe Francophone Du My\u00e9lome (IFM)","volume":"138","author":"Perrot","year":"2021","journal-title":"Blood"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e861","DOI":"10.1016\/S2352-3026(20)30323-9","article-title":"Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): Long-term follow-up analysis of a randomised phase 3, open-label study","volume":"7","author":"Tacchetti","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/ejh.12829","article-title":"Association between complete response and outcomes in transplant-eligible myeloma patients in the era of novel agents","volume":"98","author":"Londhe","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1200\/JCO.19.01231","article-title":"Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma","volume":"38","author":"Paiva","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1182\/blood.2020007522","article-title":"Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma","volume":"136","author":"Jasielec","year":"2020","journal-title":"Blood"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1182\/blood.2021010744","article-title":"Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: The IFM KRd final results","volume":"138","author":"Roussel","year":"2021","journal-title":"Blood"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1182\/blood-2021-147897","article-title":"Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2","volume":"138","author":"Loiseau","year":"2021","journal-title":"Blood"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1182\/blood-2021-149024","article-title":"Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance","volume":"138","author":"Laubach","year":"2021","journal-title":"Blood"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1200\/JCO.21.01045","article-title":"Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma","volume":"39","author":"Sonneveld","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41408-021-00498-0","article-title":"Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02\/HOVON 95 MM trial","volume":"11","author":"Oliva","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/JCO.18.00685","article-title":"Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial","volume":"37","author":"Stadtmauer","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"8506","DOI":"10.1200\/JCO.2020.38.15_suppl.8506","article-title":"Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM)","volume":"38","author":"Hari","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","article-title":"Autologous haematopoietic stem-cell transplantation versus bortezomib\u2013melphalan\u2013prednisone, with or without bortezomib\u2013lenalidomide\u2013dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): A multicentre, randomised, open-label, phase 3 study","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/jamaoncol.2017.4600","article-title":"Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis","volume":"4","author":"Dhakal","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma","volume":"335","author":"Attal","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"9227","DOI":"10.1200\/JCO.2005.03.0551","article-title":"High-Dose Therapy and Autologous Blood Stem-Cell Transplantation Compared With Conventional Treatment in Myeloma Patients Aged 55 to 65 Years: Long-Term Results of a Randomized Control Trial From the Group Myelome-Autogreffe","volume":"23","author":"Fermand","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous Transplantation and Maintenance Therapy in Multiple Myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S1470-2045(15)00389-7","article-title":"Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: A randomised, multicentre, phase 3 trial","volume":"16","author":"Gay","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1182\/blood.V128.22.991.991","article-title":"Upfront Single Versus Double Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02\/HO95 MM Trial)","volume":"128","author":"Cavo","year":"2016","journal-title":"Blood"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"8000","DOI":"10.1200\/JCO.2016.34.15_suppl.8000","article-title":"Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02\/HO95 MM trial)","volume":"34","author":"Cavo","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"LBA-1","DOI":"10.1182\/blood.V128.22.LBA-1.LBA-1","article-title":"Comparison of Autologous Hematopoietic Cell Transplant (autoHCT), Bortezomib, Lenalidomide (Len) and Dexamethasone (RVD) Consolidation with Len Maintenance (ACM), Tandem Autohct with Len Maintenance (TAM) and Autohct with Len Maintenance (AM) for up-Front Treatment of Patients with Multiple Myeloma (MM): Primary Results from the Randomized Phase III Trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702-StaMINA Trial)","volume":"128","author":"Stadtmauer","year":"2016","journal-title":"Blood"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1002\/cncr.32060","article-title":"Is there still a role for stem cell transplantation in multiple myeloma?","volume":"125","author":"Mina","year":"2019","journal-title":"Cancer"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1182\/blood-2005-03-1301","article-title":"High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: Long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA","volume":"106","author":"Sureda","year":"2005","journal-title":"Blood"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2004-02-0408","article-title":"Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: Results of a randomized controlled trial","volume":"104","author":"Palumbo","year":"2004","journal-title":"Blood"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","article-title":"Standard Chemotherapy Compared with High-Dose Chemoradiotherapy for Multiple Myeloma: Final Results of Phase III US Intergroup Trial S9321","volume":"24","author":"Barlogie","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_139","first-page":"2144","article-title":"Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: A prospective randomized phase 3 study","volume":"101","author":"Segeren","year":"2003","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Nunnelee, J., Cottini, F., Zhao, Q., Faisal, M.S., Elder, P., Rosko, A., Bumma, N., Khan, A., Devarakonda, S., and Benson, D.M. (2022). Improvement in Post-Autologous Stem Cell Transplant Survival of Multiple Myeloma Patients: A Long-Term Institutional Experience. Cancers, 14.","DOI":"10.3390\/cancers14092277"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/CCO.0b013e328324bc04","article-title":"Stem cell transplantation for multiple myeloma","volume":"21","author":"Kumar","year":"2009","journal-title":"Curr. Opin. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/j.bbmt.2015.09.016","article-title":"American society of blood and marrow transplantation, european society of blood and marrow transplantation, blood and marrow transplant clinical trials network, and international myeloma working group consensus conference on salvage hematopoietic cell transplantation in patients with relapsed multiple myeloma","volume":"21","author":"Giralt","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Mor\u00e8, S., Corvatta, L., Manieri, V.M., Saraceni, F., Scortechini, I., Mancini, G., Fiorentini, A., Olivieri, A., and Offidani, M. (2022). Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go?. Cells, 11.","DOI":"10.3390\/cells11040606"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-021-00469-5","article-title":"CAR T-cell therapy in multiple myeloma: More room for improvement","volume":"11","author":"Teoh","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2147\/BLCTT.S327016","article-title":"CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges","volume":"12","author":"Rendo","year":"2022","journal-title":"Blood Lymphat. Cancer"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1182\/blood-2021-146060","article-title":"Updated Results from CARTITUDE-1: Phase 1b\/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"138","author":"Martin","year":"2021","journal-title":"Blood"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1182\/blood-2021-146210","article-title":"Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed By Ciltacabtagene Autoleucel Versus Vrd Followed By Lenalidomide and Dexamethasone (Rd) Maintenance in Patients with Newly Diagnosed Multiple Myeloma Not Intended for Transplant: A Randomized, Phase 3 Study (CARTITUDE-5)","volume":"138","author":"Dytfeld","year":"2021","journal-title":"Blood"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1111\/ajt.14731","article-title":"Plasma cell diseases and organ transplant: A comprehensive review","volume":"18","author":"Cowan","year":"2018","journal-title":"Am. J. Transplant."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_150","first-page":"1460","article-title":"AL amyloidosis: Advances in diagnostics and treatment","volume":"34","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/bloodadvances.2018016402","article-title":"Epidemiology of AL amyloidosis: A real-world study using US claims data","volume":"2","author":"Quock","year":"2018","journal-title":"Blood Adv."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1182\/blood.V79.7.1817.1817","article-title":"Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989 [see comments]","volume":"79","author":"Kyle","year":"1992","journal-title":"Blood"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2169\/internalmedicine.9206-17","article-title":"Nationwide Survey of 741 Patients with Systemic Amyloid Light-chain Amyloidosis in Japan","volume":"57","author":"Shimazaki","year":"2018","journal-title":"Intern. Med."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1182\/blood.V88.7.2801.bloodjournal8872801","article-title":"Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: One-year follow-up in five patients","volume":"88","author":"Comenzo","year":"1996","journal-title":"Blood"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/bjh.12191","article-title":"Light chain amyloidosis 2012: A new era","volume":"160","author":"Gatt","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1080\/17474086.2022.2115353","article-title":"Recent guidelines for high-dose chemotherapy and autologous stem cell transplant for systemic AL amyloidosis: A practitioner\u2019s perspective","volume":"15","author":"Bomsztyk","year":"2022","journal-title":"Expert. Rev. Hematol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.bmt.1704346","article-title":"High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: Results of a prospective randomized trial","volume":"33","author":"Sanchorawala","year":"2004","journal-title":"Bone Marrow Transplant."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bjh.16143","article-title":"A 24-year experience of autologous stem cell transplantation for light chain amyloidosis patients in the United Kingdom","volume":"187","author":"Sharpley","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1056\/NEJMoa070484","article-title":"High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis","volume":"357","author":"Jaccard","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1159\/000506498","article-title":"High-Dose Melphalan and Autologous Peripheral Blood Stem Cell Transplantation in AL Amyloidosis","volume":"143","author":"Sanchorawala","year":"2020","journal-title":"Acta Haematol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41408-021-00486-4","article-title":"Comprehensive Review of AL amyloidosis: Some practical recommendations","volume":"11","author":"Bazarbachi","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1182\/blood-2011-01-330738","article-title":"Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: Long-term results in a series of 421 patients","volume":"118","author":"Cibeira","year":"2011","journal-title":"Blood"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/bmt.2017.68","article-title":"Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: Impact on response and survival","volume":"52","author":"Tandon","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/bjh.16096","article-title":"Ten-year survivors in AL amyloidosis: Characteristics and treatment pattern","volume":"187","author":"Muchtar","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.bbmt.2009.01.022","article-title":"Role of High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation in Primary Systemic Amyloidosis: A Systematic Review","volume":"15","author":"Mhaskar","year":"2009","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Carreras, E., Dufour, C., Mohty, M., and Kr\u00f6ger, N. (2019). The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies, Springer International Publishing.","DOI":"10.1007\/978-3-030-02278-5"},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Huang, X., Wang, Q., Chen, W., Zeng, C., Chen, Z., Gong, D., Zhang, H., and Liu, Z. (2014). Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: A randomized controlled trial. BMC Med., 12.","DOI":"10.1186\/1741-7015-12-2"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/bmt.2014.115","article-title":"Auto-SCT improves survival in systemic light chain amyloidosis: A retrospective analysis with 14-year follow-up","volume":"49","author":"Parmar","year":"2014","journal-title":"Bone Marrow Transplant."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1200\/JCO.2015.62.4015","article-title":"Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study","volume":"33","author":"Dispenzieri","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.bbmt.2015.04.001","article-title":"Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial","volume":"21","author":"Sanchorawala","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3324\/haematol.2014.119198","article-title":"Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology","volume":"100","author":"Hazenberg","year":"2015","journal-title":"Haematologica"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/leu.2016.229","article-title":"Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis","volume":"31","author":"Landau","year":"2017","journal-title":"Leukemia"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.2215\/CJN.02740806","article-title":"Light-Chain (AL) Amyloidosis: Diagnosis and Treatment","volume":"1","author":"Sanchorawala","year":"2006","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_174","unstructured":"American Society of Hematology (2019, June 28). Autologous Stem Cell Transplantation, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-daratumumab-multiple-myeloma-ineligible-autologous-stem-cell-transplant."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2012-02-408898","article-title":"Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma","volume":"120","author":"Cavo","year":"2012","journal-title":"Blood"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.bbmt.2015.03.002","article-title":"Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation","volume":"21","author":"Shah","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","article-title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"131","author":"Herrera","year":"2018","journal-title":"Blood"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1182\/blood-2016-01-629790","article-title":"What is new in diagnosis and management of light chain amyloidosis?","volume":"128","author":"Palladini","year":"2016","journal-title":"Blood"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1182\/asheducation-2018.1.75","article-title":"Novel therapies for relapsed\/refractory aggressive lymphomas","volume":"2018","author":"Cohen","year":"2018","journal-title":"Hematology"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/ajh.25819","article-title":"Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment","volume":"95","author":"Gertz","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N. Engl. J. Med."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/24\/2855\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:40:31Z","timestamp":1760132431000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/24\/2855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,18]]},"references-count":181,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["cells12242855"],"URL":"https:\/\/doi.org\/10.3390\/cells12242855","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,18]]}}}